JP2012519008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519008A5 JP2012519008A5 JP2011552364A JP2011552364A JP2012519008A5 JP 2012519008 A5 JP2012519008 A5 JP 2012519008A5 JP 2011552364 A JP2011552364 A JP 2011552364A JP 2011552364 A JP2011552364 A JP 2011552364A JP 2012519008 A5 JP2012519008 A5 JP 2012519008A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- parvovirus
- polypeptide
- cds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 claims description 114
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 claims description 114
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 claims description 114
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 claims description 114
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 claims description 114
- 150000007523 nucleic acids Chemical class 0.000 claims description 66
- 239000002245 particle Substances 0.000 claims description 65
- 241000125945 Protoparvovirus Species 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 53
- 108020004707 nucleic acids Proteins 0.000 claims description 51
- 102000039446 nucleic acids Human genes 0.000 claims description 51
- 230000035772 mutation Effects 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108091081024 Start codon Proteins 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 108700026244 Open Reading Frames Proteins 0.000 claims description 12
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 11
- 101710081079 Minor spike protein H Proteins 0.000 claims description 11
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 11
- 101710132601 Capsid protein Proteins 0.000 claims description 10
- 101710197658 Capsid protein VP1 Proteins 0.000 claims description 10
- 101710172711 Structural protein Proteins 0.000 claims description 10
- 101710108545 Viral protein 1 Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000037431 insertion Effects 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 210000000234 capsid Anatomy 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 230000014621 translational initiation Effects 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000037432 silent mutation Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 206010012335 Dependence Diseases 0.000 claims description 2
- 241000684283 Duck parvovirus Species 0.000 claims description 2
- 241001517118 Goose parvovirus Species 0.000 claims description 2
- 241000425549 Snake parvovirus Species 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 101710136297 Protein VP2 Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 8
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 8
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 8
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 4
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000649047 Adeno-associated virus 12 Species 0.000 description 1
- 241000300529 Adeno-associated virus 13 Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- -1 VP3 Nucleic acid Chemical class 0.000 description 1
- 108091027569 Z-DNA Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15743609P | 2009-03-04 | 2009-03-04 | |
| US61/157,436 | 2009-03-04 | ||
| US30620510P | 2010-02-19 | 2010-02-19 | |
| US61/306,205 | 2010-02-19 | ||
| PCT/EP2010/001343 WO2010099960A2 (en) | 2009-03-04 | 2010-03-04 | Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essential consisting of vp3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015200962A Division JP6151328B2 (ja) | 2009-03-04 | 2015-10-09 | 集合活性化タンパク質（ａａｐ）およびｖｐ３から本質的になるパルボウイルス粒子を製造するためのａａｐの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012519008A JP2012519008A (ja) | 2012-08-23 |
| JP2012519008A5 true JP2012519008A5 (cg-RX-API-DMAC10.html) | 2013-04-11 |
Family
ID=42313642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552364A Pending JP2012519008A (ja) | 2009-03-04 | 2010-03-04 | 集合活性化タンパク質（ａａｐ）およびｖｐ３から本質的になるパルボウイルス粒子を製造するためのａａｐの使用 |
| JP2015200962A Expired - Fee Related JP6151328B2 (ja) | 2009-03-04 | 2015-10-09 | 集合活性化タンパク質（ａａｐ）およびｖｐ３から本質的になるパルボウイルス粒子を製造するためのａａｐの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015200962A Expired - Fee Related JP6151328B2 (ja) | 2009-03-04 | 2015-10-09 | 集合活性化タンパク質（ａａｐ）およびｖｐ３から本質的になるパルボウイルス粒子を製造するためのａａｐの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9464119B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2403867B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2012519008A (cg-RX-API-DMAC10.html) |
| CN (1) | CN102341406B (cg-RX-API-DMAC10.html) |
| BR (1) | BRPI1013364A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2754335C (cg-RX-API-DMAC10.html) |
| DK (1) | DK2403867T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2742180T3 (cg-RX-API-DMAC10.html) |
| MX (2) | MX345729B (cg-RX-API-DMAC10.html) |
| PL (1) | PL2403867T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT2403867T (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010099960A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2754335C (en) | 2009-03-04 | 2019-12-24 | Medigene Ag | Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3 |
| EP2534172A2 (en) * | 2010-02-12 | 2012-12-19 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Compositions and methods for preventing or treating a human parvovirus infection |
| AR082925A1 (es) * | 2010-09-08 | 2013-01-16 | Medigene Ag | Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados |
| RU2487708C1 (ru) * | 2012-03-12 | 2013-07-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) | Способ лечения парвовирусной инфекции в19 у детей раннего возраста |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| ES2822551T3 (es) | 2014-03-17 | 2021-05-04 | Adverum Biotechnologies Inc | Composiciones y métodos para la expresión génica mejorada en células de los conos |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP3215191B1 (en) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| FI3265178T3 (fi) | 2015-03-02 | 2026-08-03 | Adverum Biotechnologies Inc | Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| EP4134375A1 (en) | 2015-07-30 | 2023-02-15 | Massachusetts Eye & Ear Infirmary | Ancestral adeno associated virus sequences and uses thereof |
| GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| EP3831281B1 (en) | 2016-08-30 | 2026-02-25 | The Regents of The University of California | Devices and systems for biomedical targeting and delivery |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN111511375A (zh) * | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | 用于基因治疗的腺相关病毒载体 |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| US20200231986A1 (en) * | 2017-09-29 | 2020-07-23 | Massachusetts Eye And Ear Infirmary | Production of adeno-associated viruses in insect cells |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| US20190202866A1 (en) * | 2017-12-22 | 2019-07-04 | William Marsh Rice University | Viral nanoparticles and methods of use thereof |
| CN112074295A (zh) | 2018-02-16 | 2020-12-11 | 2A制药公司 | 用于治疗自身免疫性疾病的细小病毒结构蛋白 |
| EP3527223A1 (en) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutated parvovirus structural protein |
| US12421525B2 (en) | 2018-02-28 | 2025-09-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Conjugates comprising AAVs and CAS9 polypeptides |
| WO2019195549A1 (en) * | 2018-04-04 | 2019-10-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for engineered assembly activating proteins (eaaps) |
| WO2019195701A1 (en) | 2018-04-05 | 2019-10-10 | Massachusetts Eye And Ear Infirmary | Methods of making and using combinatorial barcoded nucleic acid libraries having defined variation |
| US20210363192A1 (en) * | 2018-04-27 | 2021-11-25 | Spark Therapeutics, Inc. | Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2020142236A1 (en) * | 2019-01-02 | 2020-07-09 | Intima Bioscience, Inc. | Modified adeno-associated viral vectors for use in genetic engineering |
| CN113795575A (zh) | 2019-02-04 | 2021-12-14 | 自由行疗法有限公司 | 多核苷酸 |
| KR20210126096A (ko) | 2019-02-15 | 2021-10-19 | 상가모 테라퓨틱스, 인코포레이티드 | 재조합 aav를 제조하기 위한 조성물 및 방법 |
| CA3136545A1 (en) * | 2019-04-12 | 2020-10-15 | Freeline Therapeutics Limited | Plasmid system |
| CA3170169A1 (en) * | 2020-02-07 | 2021-08-12 | Vecprobio, Inc. | Recombinant adeno-associated viral vectors in plants |
| WO2021260204A1 (en) * | 2020-06-25 | 2021-12-30 | Ferring Ventures Sa | Improved adeno-associated virus gene therapy vectors |
| WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
| CN117343943A (zh) * | 2022-10-13 | 2024-01-05 | 康霖生物科技（杭州）有限公司 | 腺相关病毒的衣壳蛋白编码基因改造方法 |
| CN117126270B (zh) * | 2023-10-25 | 2024-02-13 | 首都儿科研究所 | 一种2型人博卡病毒型别特异性抗体及其应用 |
| WO2025125222A1 (en) | 2023-12-11 | 2025-06-19 | Leukocare Ag | Compositions comprising viruses, viral vectors or virus-like particles |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4168062A (en) | 1977-12-05 | 1979-09-18 | Mccarthy Gerald F | Automated goalie |
| US6027722A (en) * | 1990-10-25 | 2000-02-22 | Nature Technology Corporation | Vectors for gene transfer |
| DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
| US20020052040A1 (en) * | 1999-06-30 | 2002-05-02 | Nicholas Hunt | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| DE19933719A1 (de) | 1999-07-19 | 2001-01-25 | Medigene Ag | Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung |
| JP2001169777A (ja) | 1999-07-30 | 2001-06-26 | Hiroshi Handa | アデノ随伴ウイルスのｖｐ３キャプシド蛋白質からウイルス様粒子を形成する方法 |
| US7638120B2 (en) * | 2000-03-14 | 2009-12-29 | Thomas Jefferson University | High transgene expression of a pseudotyped adeno-associated virus type |
| DE10024334B4 (de) | 2000-05-17 | 2006-06-01 | Medigene Ag | Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| US7749492B2 (en) * | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
| CA2453405A1 (en) * | 2001-07-13 | 2003-01-23 | University Of Iowa Research Foundation | Pseudotyped adeno-associated viruses and uses thereof |
| SI1496944T1 (sl) * | 2002-05-01 | 2009-02-28 | Univ Florida | Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov |
| US20060093589A1 (en) * | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
| WO2004000220A2 (en) * | 2002-06-21 | 2003-12-31 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
| EP2158211B1 (en) | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| CA2754335C (en) | 2009-03-04 | 2019-12-24 | Medigene Ag | Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3 |
-
2010
- 2010-03-04 CA CA2754335A patent/CA2754335C/en active Active
- 2010-03-04 PT PT10708716T patent/PT2403867T/pt unknown
- 2010-03-04 EP EP10708716.5A patent/EP2403867B1/en active Active
- 2010-03-04 US US13/203,442 patent/US9464119B2/en active Active
- 2010-03-04 WO PCT/EP2010/001343 patent/WO2010099960A2/en not_active Ceased
- 2010-03-04 MX MX2014014365A patent/MX345729B/es unknown
- 2010-03-04 MX MX2011009193A patent/MX2011009193A/es active IP Right Grant
- 2010-03-04 JP JP2011552364A patent/JP2012519008A/ja active Pending
- 2010-03-04 BR BRPI1013364A patent/BRPI1013364A2/pt not_active Application Discontinuation
- 2010-03-04 PL PL10708716T patent/PL2403867T3/pl unknown
- 2010-03-04 CN CN201080010540.8A patent/CN102341406B/zh active Active
- 2010-03-04 DK DK10708716.5T patent/DK2403867T3/da active
- 2010-03-04 ES ES10708716T patent/ES2742180T3/es active Active
-
2015
- 2015-10-09 JP JP2015200962A patent/JP6151328B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-12 US US15/263,072 patent/US10344057B2/en active Active
-
2019
- 2019-05-17 US US16/415,676 patent/US11267847B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7395550B2 (ja) | 新規アデノ随伴ウイルスキャプシドタンパク質 | |
| US20240197918A1 (en) | Tissue-targeted modified aav capsids and methods of use thereof | |
| CN102341406B (zh) | 组装活化蛋白（aap）及其用于制备基本上由vp3组成的细小病毒颗粒的应用 | |
| US20230020565A1 (en) | Novel compositions and methods for producing recombinant aav | |
| JP2020511127A5 (cg-RX-API-DMAC10.html) | ||
| AU2018303230A1 (en) | Improved AAV capsid production in insect cells | |
| TW202005978A (zh) | 新穎肝靶向腺相關病毒載體 | |
| JP2022520803A5 (cg-RX-API-DMAC10.html) | ||
| JP2014239686A5 (cg-RX-API-DMAC10.html) | ||
| AU2019231711A1 (en) | AAV chimeras | |
| WO2021108468A1 (en) | Novel aav3b variants that target human hepatocytes in the liver of humanized mice | |
| CA3025445A1 (en) | Dual overlapping adeno-associated viral vector system for expressing abc4a | |
| WO2021183895A1 (en) | Treatment of fabry disease with aav gene therapy vectors | |
| CN106701691B (zh) | 一种可高效感染免疫细胞的aav病毒及其制备方法与应用 | |
| WO2025051189A2 (en) | Human embryonic kidney cell lines and use thereof in producing raav | |
| Nambiar | Isolation and Characterization of Novel Adeno-Associated Viruses for the Advancement of Gene Therapy | |
| CA3124880C (en) | Gene therapy constructs for treating wilson disease | |
| RU2779318C2 (ru) | Новые капсидные белки адено-ассоциированного вируса | |
| CN119331061A (zh) | 靶向中枢神经系统的aav衣壳蛋白变体及其用途 | |
| JP2024511851A (ja) | 改変血漿凝固第ｖｉｉｉ因子およびその使用方法 | |
| JP2023543356A (ja) | 組成物およびその使用 | |
| RU2021126774A (ru) | Модуляция активности rep белка при получении днк с замкнутыми концами (зкднк) | |
| CA3124880A1 (en) | Gene therapy constructs for treating wilson disease | |
| EA042960B1 (ru) | Молекула нуклеиновой кислоты, конструкция нуклеиновой кислоты, клетка насекомого и способ получения aav в клетке насекомого | |
| NZ738841A (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |